ClinicaliQ Trial Snapshot
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) — Active Not Recruiting • Phase III • NCT05248646.
- A drug injected under the skin was tested to see if it could reduce kidney damage and was safe in patients with IgA nephropathy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy Conditions: Immunoglobulin A Nephropathy Interventions: Sibeprenlimab 400 mg, Placebo Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Planned Enrollment: 530 participants